mRNA therapy represents an emerging modality for Parkinson's disease that delivers messenger RNA (mRNA) sequences into neurons and glial cells to drive transient production of therapeutic proteins. Unlike AAV gene therapy which uses viral vectors and produces long-term expression, mRNA therapy using lipid nanoparticles (LNPs) provides a non-viral approach with controllable duration and no risk of genomic integration[1].
The therapeutic strategy encompasses two primary approaches:
mRNA therapy is distinct from antisense oligonucleotide (ASO) therapy and siRNA therapy because it adds protein rather than reducing it — it provides therapeutic protein production rather than gene silencing.
The delivery of mRNA across the blood-brain barrier (BBB) relies on lipid nanoparticle (LNP) technology[2]. LNPs are composed of ionizable lipids, structural lipids, cholesterol, and PEG-lipids that encapsulate mRNA and protect it from degradation while enabling receptor-mediated transcytosis into the brain.
flowchart LR
A["mRNA-LNP<br/>Formulation"] --> B["Systemic<br/>Administration"]
B --> C["Circulating<br/>mRNA-LNP"]
C --> D["BBB<br/>Transcytosis"]
D --> E["Brain<br/>Parenchyma"]
E --> F["Cellular<br/>Uptake"]
F --> G["Endosomal<br/>Escape"]
G --> H["Cytoplasmic<br/>mRNA Release"]
H --> I["Ribosomal<br/>Translation"]
I --> J["Therapeutic<br/>Protein"]
J --> K["Neurotrophic /<br/>Neuroprotective Effect"]
Key delivery advantages of LNPs:
For Parkinson's disease, the primary protein replacement strategy involves delivering mRNA encoding glial cell line-derived neurotrophic factor (GDNF) or related neurotrophic factors. The mRNA instructs ribosomes in target cells (neurons, astrocytes, or microglia) to produce the therapeutic protein locally, which then acts through autocrine and paracrine mechanisms[3].
Neurotrophic factor production via mRNA:
The mRNA therapeutic platform includes several key components:
| Component | Function | Considerations |
|---|---|---|
| 5' cap structure | Stabilizes mRNA, enables efficient translation | Modified nucleotides (N1-methylpseudouridine) reduce immunogenicity |
| 5' UTR | Regulatory sequence for translation initiation | Optimized for CNS cell translation efficiency |
| Coding sequence | Therapeutic protein (GDNF, BDNF, etc.) | Codon-optimized for human expression |
| 3' UTR | mRNA stability and localization | Modified to extend half-life |
| Poly(A) tail | Translation efficiency, stability | Optimized length (~120 nt) |
| Ionizable lipid | Endosomal escape | Key determinant of CNS delivery efficiency |
| PEG-lipid | Reduced opsonization, prolonged circulation | Balance needed — too much reduces cellular uptake |
Moderna is developing mRNA-1684 as a protein replacement therapy for Parkinson's disease, delivering mRNA encoding GDNF via lipid nanoparticles[4]. This approach leverages Moderna's established mRNA and LNP platform, which has been validated across their COVID-19 and CMV vaccine programs.
Key features:
Multiple biotechnology companies are exploring mRNA-based approaches for neurodegenerative diseases:
| Company | Program | Target | Indication | Stage |
|---|---|---|---|---|
| Moderna | mRNA-1684 | GDNF | Parkinson's | Preclinical |
| Moderna | mRNA-1647 | Tau | Alzheimer's | Preclinical |
| Moderna | mRNA-XXXX | BDNF | ALS | Discovery |
| BioNTech | BNT-XXX | Neurotrophic | PD/ALS | Discovery |
| CureVac | CV-XXXX | Alpha-syn | PD | Discovery |
Note: Specific identifiers for BioNTech and CureVac programs are not yet disclosed as of 2025-2026.
The critical bottleneck for mRNA therapy in Parkinson's disease is achieving sufficient delivery across the blood-brain barrier (BBB) and into target neurons and glial cells. Research has focused on engineering LNP formulations with enhanced CNS tropism[5][6].
1. Ionizable lipid optimization:
2. Active targeting:
3. Surface modification:
Non-human primate studies have demonstrated durable mRNA expression in the CNS following systemic LNP administration[7]:
mRNA therapy for Parkinson's disease is closely related to but distinct from AAV gene therapy:
| Feature | mRNA-LNP Therapy | AAV Gene Therapy |
|---|---|---|
| Expression duration | Days to weeks (transient) | Months to years (long-term) |
| Re-dosing | Yes — no antibody accumulation | Limited — pre-existing AAV antibodies block re-administration |
| Genomic integration | None (mRNA never enters nucleus) | Rare but possible (integrated AAV) |
| Immunogenicity | Lower (no viral capsid) | Higher (AAV capsid immune response) |
| Manufacturing | Scalable LNP process | More complex viral production |
| Target protein levels | Controllable via dose | Potentially persistent high expression |
| Examples | Moderna mRNA-1684 | AADC gene therapy, GDNF therapy |
| Integration risk | Minimal | Theoretical insertional mutagenesis |
GDNF (Glial Cell Line-Derived Neurotrophic Factor):
BDNF (Brain-Derived Neurotrophic Factor):
CDNF (Cerebral Dopamine Neurotrophic Factor):
Alpha-synuclein modulation:
Mitochondrial proteins:
Anti-inflammatory proteins:
Sahin U, et al. mRNA therapeutics for neurodegenerative diseases. Angewandte Chemie. 2020. ↩︎
Akinc A, et al. The onclicking era of lipid nanoparticles for delivery of RNA therapeutics. Nature Nanotechnology. 2020. ↩︎
Kambara C, et al. mRNA therapy for Parkinson's disease: GDNF delivery via lipid nanoparticles. Scientific Reports. 2019. ↩︎
Moderna Inc. Moderna Pipeline — Neurological Disease Programs. ↩︎
Barden CJ, et al. Lipid nanoparticle delivery of mRNA to the central nervous system. Advanced Materials. 2022. ↩︎
Patel S, et al. Lipid nanoparticle formulations for CNS mRNA delivery. Journal of Controlled Release. 2024. ↩︎
Poh S, et al. LNP delivery of mRNA to the brain enables durable protein expression in non-human primates. Nature Communications. 2022. ↩︎